{
    "clinical_study": {
        "@rank": "163355", 
        "brief_summary": {
            "textblock": "To investigate the safety of polyethylene glycolated interleukin-2 (PEG IL-2) given\n      subcutaneously in conjunction with antiviral treatment and to explore the effects of\n      treatment on surrogate markers of efficacy and incidence of opportunistic infection and\n      other clinical markers of HIV disease."
        }, 
        "brief_title": "Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "Four escalating doses of PEG IL-2 are studied. Patients are stratified by CD4 level. CD4\n      levels in Group A are 200 to 500 cells/mm3; in Group B - 1 to less than 200 cells/mm3.\n      Further stratification is by p24 positive or negative, antiviral therapy for more or less\n      than a year, and zidovudine (AZT) versus didanosine (ddI). The duration of PEG IL-2\n      treatment is a maximum of 28 weeks. This is an outpatient study; patients will be observed\n      for four hours after the first dose of PEG IL-2 and for one hour after subsequent doses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV seropositivity by commercially available ELISA.\n\n          -  Meet Disease Status criteria.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Concurrent neoplasms other than basal cell carcinoma of the skin, in-situ carcinoma\n             of the cervix or limited cutaneous Kaposi's sarcoma.\n\n          -  Recently treated HIV-related lymphoma.\n\n          -  Major organ allograft.\n\n          -  Presence of space occupying central nervous system (CNS) lesions or other conditions\n             which would be anticipated to cause cerebral edema.\n\n          -  Renal compromise or use of drug therapy anticipated to lead to renal compromise.\n\n          -  Active opportunistic infection requiring hospitalization or exclude medication.\n\n          -  Requiring continual acyclovir for suppression of herpes infection.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Acyclovir.\n\n          -  Drug therapy anticipated to lead to renal compromise.\n\n        Patients with the following are excluded:\n\n          -  Intolerance to zidovudine (AZT) at 300 mg/day divided q8h or didanosine (ddI) at 7\n             mg/kg/day given twice a day.\n\n          -  History of HIV-related lymphoma.\n\n          -  History of asthma requiring frequent therapy, chronic pulmonary disease, hypertension\n             requiring therapy, or congestive heart failure.\n\n          -  Any of the symptoms or conditions listed in Exclusion - Co-Existing Conditions.\n\n        Prior Medication:\n\n        Excluded:\n\n        - Any prior therapy with interleukin-2 (IL-2) or PEG IL-2.\n\n        Excluded 30 days prior to study entry:\n\n        - Treatment with other anti-HIV medication or known immunomodulators or other chemotherapy\n        or radiation therapy.\n\n        Active substance abuse so patients would be anticipated to be poorly compliant with\n        protocol requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001997", 
            "org_study_id": "072B", 
            "secondary_id": "CS-PG91-07"
        }, 
        "intervention": [
            {
                "intervention_name": "Interleukin-2, Polyethylene Glycolated", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Zidovudine", 
                "Interleukin-2"
            ]
        }, 
        "keyword": [
            "Recombinant Proteins", 
            "Polyethylene Glycols", 
            "Interleukin-2", 
            "Didanosine", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94108"
                }, 
                "name": "Dr David R Senechek"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001997"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiron Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1991"
    }, 
    "geocoordinates": {
        "Dr David R Senechek": "37.775 -122.419"
    }
}